EU committee recommends omega-3 supplements during pregnancy
Pregnant women should take a daily supplement of omega-3 acids, an EU supported consensus committee has recommended. The supplement would increase the likelihood of a healthy birth and boost child development. The committee, composed of more than 50 nutritional experts from the EU-funded projects Perinatal Lipid Nutrition Group (PeriLip) and Early Nutrition Programming (EARNEST), said it had found that women who included DHA in their diet had healthier pregnancies, that their children had healthier birth weights and that they were less likely to give birth prematurely.
Read more ...
International Study Finds New Drugs Combination to Cut Deaths from Diabetes
The largest-ever study of treatments for diabetes has shown that a combination of two blood pressure-lowering drugs reduces the risk of death, heart attack and kidney disease in diabetes sufferers. The "Action in diabetes and vascular disease" (ADVANCE) project involves 20 countries from around the world, 12 of them from the EU. The results were presented at the European Society of Cardiology Congress in Vienna, Austria, on 3 September.
Read more ...
The Future of Pharmaceuticals for Human Use in Europe
The European pharmaceutical industry makes an irreplaceable contribution to Europe's wellbeing through the availability of medicines, economic growth and employment. The pharmaceutical sector has been and remains a key strategic sector for Europe.
Read more ...
Study Trends Online Professional Activities and Reveals Specialty-specific Marketing Opportunities
Manhattan Research, a healthcare market research services firm, announced the leading pharmaceutical product website destinations for physicians from its new physician research study, "ePharma Physician® v7.0: The Future of Professional eMarketing.". Manhattan Research recently hosted a webcast discussing highlights of the ePharma Physician® v7.0 research.
Read more ...
Putnam Associates Study Finds Insurers Want More Prescription Drug Use
Putnam Associates released today the results of an intensive study of U.S. health insurance plans' perceptions of branded prescription drug use in the U.S. The study revealed that plans believe greater pharmacoeconomic value can be unlocked by increasing patient use within certain drug categories.
Read more ...
Patients and Healthcare Providers to Experience Significant Benefits from the Use of the Internet
The growth of Internet applications in healthcare has been rapid. A growing number of patients are becoming increasingly involved in the healthcare service they receive. These 'power patients' possess characteristics that distinguish them from traditional patients and are an important factor in driving the use of the Internet in healthcare.
Read more ...
Merck's Investigational Integrase Inhibitor for HIV
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ISENTRESS™ (raltegravir, previously known as MK-0518). Data in the NDA support the proposed use of ISENTRESS in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy (ART).
Read more ...
The European pharmaceutical industry makes an irreplaceable contribution to Europe's wellbeing through the availability of medicines, economic growth and employment. The pharmaceutical sector has been and remains a key strategic sector for Europe. 
Manhattan Research, a healthcare market research services firm, announced the leading pharmaceutical product website destinations for physicians from its new physician research study, "ePharma Physician® v7.0: The Future of Professional eMarketing.". Manhattan Research recently hosted a webcast discussing highlights of the ePharma Physician® v7.0 research. 
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ISENTRESS™ (raltegravir, previously known as MK-0518). Data in the NDA support the proposed use of ISENTRESS in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy (ART).